Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW ORLEANS , July 28, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company's securities between January 5, 2023 to June 5, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR

OAKLAND, Calif.--(BUSINESS WIRE)---- $NVCR #NVCR--Gibbs Law Group announces that a class action lawsuit has been filed on behalf of NovoCure Limited (NASDAQ: NVCR) investors. On June 6, 2023, NovoCure announced results from its Phase 3 LUNAR clinical trial that some doctors say may have included unreliable data, because not all study participants had been receiving standard of care therapy, according to Evaluate. Gibbs Law Group encourages NovoCure investors to contact us to discuss their legal rights and opti.

Lost Money in NovoCure Limited? Gibbs Law Group Investigates Potential Securities Law Violations

The cancer-focused biotech published its second-quarter results. These fell short of analyst expectations, unfortunately.

Why Novocure Stock Tumbled by Nearly 16% Today

NEW YORK , July 27, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the "Class Period"), of the important August 18, 2023 lead plaintiff deadline. SO WHAT: If you purchased NovoCure securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NVCR NOTICE: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR

LOS ANGELES, CA / ACCESSWIRE / July 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm

NovoCure Limited (NASDAQ:NVCR ) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Company Participants Ingrid Goldberg - VP of IR William Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Pritesh Shah - Chief Growth Officer Conference Call Participants Jason Bednar - Piper Sandler Emily Bodnar - H.C. Wainwright Operator Good day, and thank you for standing by.

NovoCure Limited (NVCR) Q2 2023 Earnings Call Transcript

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today reported financial results for the quarter ended June 30, 2023.

Novocure Reports Second Quarter 2023 Financial Results

LOS ANGELES, CA / ACCESSWIRE / July 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm

In early June, NovoCure's stock dropped 43% in a single day after the company presented the LUNAR study at ASCO. The stock now trades near 5-year lows. What caused the drop exactly? And is this the end of the story for NovoCure? The details of the results and the implications of the details for investors will be discussed.

NovoCure At 5 Year Lows: Avoid Or Opportunity?

Did you lose money on investments in NovoCure Limited?  If so, please visit NovoCure Limited Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

NOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NovoCure Limited

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial.

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

INVESTOR DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm

NEW YORK , July 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the "Class Period"), of the important August 18, 2023 lead plaintiff deadline. SO WHAT: If you purchased NovoCure securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR

LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm

NEW YORK , July 8, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the "Class Period"), of the important August 18, 2023 lead plaintiff deadline. SO WHAT: If you purchased NovoCure securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR

LOS ANGELES, CA / ACCESSWIRE / July 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 5, 2023 and June 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 18, 2023.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm

Novocure published the results of an important phase 3 clinical trial last month. The treatment clearly demonstrated strong results that improved outcomes for lung cancer patients.

Here's Why Novocure Stock Dropped 42% in June

SAN FRANCISCO--(BUSINESS WIRE)---- $NVCR #InvestorAlert--NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser.

NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three and six months ended June 30, 2023, at 8:00 a.m. EDT on Thursday, July 27, 2023. To access the conference call by phone, use the following conference call registration link.

Novocure to Report Second Quarter 2023 Financial Results

NEW YORK , July 1, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the "Class Period"), of the important August 18, 2023 lead plaintiff deadline. SO WHAT: If you purchased NovoCure securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NVCR

NEW YORK--(BUSINESS WIRE)---- $NVCR #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) securities during the period from January 5, 2023 through June 5, 2023 (the “Class Period”). Investors have until August 18, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit. NovoCure is an oncolog.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of NovoCure Limited (NVCR) Investors and Encourages Investors to Contact the Firm Before August 18, 2023

News for Novocure Stock (NVCR)